UBE2Q1 in a Human Breast Carcinoma Cell Line: Overexpression and Interaction with p53 |
Shafiee, Sayed Mohammad
(Departments of Biochemistry- Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences)
Rasti, Mozhgan (Departments of Biochemistry- Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences) Seghatoleslam, Atefeh (Departments of Biochemistry- Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences) Azimi, Tayebeh (Departments of Biochemistry- Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences) Owji, Ali Akbar (Departments of Biochemistry- Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences) |
1 | Bremm A, Komander D (2011). Emerging roles for Lys11-linked polyubiquitin in cellular regulation. Trends Biochem Sci, 36, 355-63. |
2 | Brooks CL, Gu W (2003). Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol, 15, 164-71. DOI |
3 | Chang R, Wei L, Lu Y, et al (2015). Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma. J Mol Histol, 46, 45-56. DOI |
4 | Chen S, Wang DL, Liu Y, et al (2012). RAD6 regulates the dosage of p53 by a combination of transcriptional and posttranscriptional mechanisms. Mol Cell Biol, 32, 576-87. DOI |
5 | Dahlmann B (2007). Role of proteasomes in disease. BMC Biochem, 8, 3. DOI |
6 | Devine T, Dai MS (2013). Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des 19, 3248-62. DOI |
7 | Gerard B, Sanders MA, Visscher DW, et al (2012). Lysine 394 is a novel Rad6B-induced ubiquitination site on beta-catenin. Biochim Biophys Acta, 1823, 1686-96. DOI |
8 | Goldstein G, Scheid M, Hammerling U, et al (1975). Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci U S A, 72, 11-5. DOI |
9 | Hoeller D, Hecker CM, Wagner S, et al (2007). E3-independent monoubiquitination of ubiquitin-binding proteins. Mol Cell, 26, 891-8. DOI |
10 | Hohenstein P, Giles RH (2003). BRCA1: a scaffold for p53 response? Trends Genet, 19, 489-94. DOI |
11 | Karami K, Cheraghi M, Amori N, et al (2014). Common cancers in Khuzestan province, south west of Iran, during 2005-2011. Asian Pac J Cancer Prev, 15, 9475-8. DOI |
12 | Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer, 13, 293-325. DOI |
13 | Lai Z, Yang T, Kim YB, et al (2002). Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA, 99, 14734-9. DOI |
14 | Moll UM, Petrenko O (2003). The MDM2-p53 interaction. Mol Cancer Res, 1, 1001-8. |
15 | Lee JT, Gu W (2010). The multiple levels of regulation by p53 ubiquitination. Cell Death Differ, 17, 86-92. DOI |
16 | Maeda H, Miyajima N, Kano S, et al (2009). Ubiquitin-conjugating enzyme UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer. Mol Cancer Res, 7, 1553-62. DOI |
17 | Mani A, Gelmann EP (2005). The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol, 23, 4776-89. DOI |
18 | Muller J, Eilers M (2008). Ubiquitination of myc: proteasomal degradation and beyond. Ernst Schering Found Symp Proc, 2008, 99-113. |
19 | Nikseresht M, Seghatoleslam A, Monabati A, et al (2010). Overexpression of the novel human gene, UBE2Q2, in breast cancer. Cancer Genet Cytogenet, 197, 101-6. DOI |
20 | Ohta T, Fukuda M (2004). Ubiquitin and breast cancer. Oncogene, 23, 2079-88. DOI |
21 | Rasti M, Arabsolghar R, Khatooni Z, et al (2012). p53 Binds to estrogen receptor 1 promoter in human breast cancer cells. Pathol Oncol Res, 18, 169-75. DOI ScienceOn |
22 | Rodriguez MS, Desterro JM, Lain S, et al (2000). Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol, 20, 8458-67. DOI |
23 | Saville MK, Sparks A, Xirodimas DP, et al (2004). Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem, 279, 42169-81. DOI |
24 | Seghatoleslam A, Bozorg-Ghalati F, Monabati A, et al (2014). UBE2Q1, as a down regulated gene in pediatric acute lymphoblastic leukemia. Int J Mol Cell Med, 3, 95-101. |
25 | Seghatoleslam A, Zambrano A, Millon R, et al (2006). Analysis of a novel human gene, LOC92912, over-expressed in hypopharyngeal tumours. Biochem Biophys Res Commun, 339, 422-9. DOI |
26 | Seghatoleslam A, Monabati A, Bozorg-Ghalati F, et al (2012a). Expression of UBE2Q2, a putative member of the ubiquitin-conjugating enzyme family in pediatric acute lymphoblastic leukemia. Arch Iran Med, 15, 352-5. |
27 | Seghatoleslam A, Nikseresht M, Shafiee SM, et al (2012b). Expression of the novel human gene, UBE2Q1, in breast tumors. Mol Biol Rep, 39, 5135-41. DOI |
28 | Seghatoleslam A, Zambrano A (2009). Effects of over-expression of LOC92912 gene on cell cycle progression. Iran J Med Sci, 34, 227-84. |
29 | Shafiee SM, Seghatoleslam A, Nikseresht M, et al (2013). UBE2Q1 expression in human colorectal tumors and cell lines. Mol Biol Rep, 40, 7045-51. DOI |
30 | Shafiee SM, Seghatoleslam A, Nikseresht M, et al (2014). Expression status of UBE2Q2 in colorectal primary tumors and cell Lines. Iran J Med Sci, 39, 196-202. |
31 | Tang XK, Wang KJ, Tang YK, et al (2014). Effects of ubiquitin-conjugating enzyme 2C on invasion, proliferation and cell cycling of lung cancer cells. Asian Pac J Cancer Prev, 15, 3005-9. DOI |
32 | Voutsadakis IA (2013). Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer. Mol Biol Rep, 40, 2019-34. DOI |
33 | Waite KA, Eng C (2003). BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet, 12, 679-84. DOI |
34 | Wan C, Chen J, Hu B, et al (2014). Downregulation of UBE2Q1 is associated with neuronal apoptosis in rat brain cortex following traumatic brain injury. J Neurosci Res, 92, 1-12. DOI |
35 | Zhu S, Yao F, Li WH, et al (2013). PKC-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion. Asian Pac J Cancer Prev, 14, 5687-92. DOI ScienceOn |
36 | Wei W, Jin J, Schlisio S, et al (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell, 8, 25-33. DOI |
37 | Yang Y, Li CC, Weissman AM (2004). Regulating the p53 system through ubiquitination. Oncogene, 23, 2096-106. DOI |